Marina Macchini

List of Publications by Year
in descending order

27 papers	1,398 citations	686830 13 h-index	525886 27 g-index
29 all docs	29 docs citations	29 times ranked	2178 citing authors

#	Article	IF	Citations
1	Nerve Growth Factor Promotes Gastric Tumorigenesis through Aberrant Cholinergic Signaling. Cancer Cell, 2017, 31, 21-34.	7.7	332
2	Î²2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Cancer Cell, 2018, 33, 75-90.e7.	7.7	287
3	Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis. Cell Stem Cell, 2016, 18, 441-455.	5.2	196
4	Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness. Cancer Discovery, 2018, 8, 1458-1473.	7.7	158
5	Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 691-697.	3.7	50
6	A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin inÂlocally advanced or borderline resectable pancreatic adenocarcinoma. European Journal of Cancer, 2018, 102, 95-102.	1.3	50
7	Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives. Cancer Treatment Reviews, 2019, 72, 1-6.	3.4	46
8	Interleukin-1Î²-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyteâ€“mediated immune suppression. Gut, 2020, 70, gutjnl-2019-319912.	6.1	32
9	State of the art biological therapies in pancreatic cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 55.	0.8	30
10	Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array. Molecular Medicine Reports, 2015, 12, 7479-7484.	1.1	20
11	Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. ESMO Open, 2021, 6, 100032.	2.0	19
12	Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses. Oncology Letters, 2016, 11, 3161-3166.	0.8	17
13	Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Critical Reviews in Oncology/Hematology, 2022, 169, 103571.	2.0	17
14	Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants. Cancer Treatment Reviews, 2021, 100, 102262.	3.4	16
15	Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): aÂmulticenter survey. ESMO Open, 2021, 6, 100238.	2.0	12
16	Preoperative Gemcitabine and Oxaliplatin in a Patient with Ovarian Metastasis from Pancreatic Cystadenocarcinoma. Case Reports in Gastroenterology, 2012, 6, 530-537.	0.3	11
17	Hedgehog signaling: From the cuirass to the heart of pancreatic cancer. Pancreatology, 2012, 12, 388-393.	0.5	9
18	Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2020, 85, 641-650.	1.1	8

#	Article	IF	Citations
19	The impact of nutritional status on pancreatic cancer therapy. Expert Review of Anticancer Therapy, 2022, 22, 155-167.	1.1	8
20	Venous Thromboembolism and Port-Related Thrombosis in Metastatic Colorectal Cancer Patients: A Monocenter Experience. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2010, 37, 30-34.	0.5	6
21	Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients. Cancer Treatment Reviews, 2022, 104, 102357.	3.4	4
22	Antiprotease Strategy in Pancreatic Cancer Treatment. Pancreas, 2014, 43, 53-63.	0.5	3
23	Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. Cancer Chemotherapy and Pharmacology, 2021, 87, 95-101.	1.1	3
24	Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2020, 10, 613582.	1.3	2
25	Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer: A literature review and report of two cases. Oncology Letters, 2011, 2, 195-200.	0.8	1
26	Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. Digestive and Liver Disease, 2021, 53, 117-121.	0.4	1
27	CTNI-51. ADJUVANT TROTABRESIB, A REVERSIBLE POTENT BROMODOMAIN AND EXTRATERMINAL INHIBITOR, PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: INTERIM RESULTS FROM A PHASE 1B DOSE-FINDING STUDY. Neuro-Oncology, 2021, 23, vi71-vi72.	0.6	0